Skip to main content

Table 1 Baseline demographic and clinical parameters

From: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

Characteristics N = 70
Age 46.9 ± 1.4
Gender
 Male 15 (21.4)
 Female 55 (78.6)
Age at migraine onset, years 14.1 ± 0.9
Disease duration, years 33.1 ± 1.2
Concurrent oral preventive treatments 40 (57)
 Monotherapy 18 (26)
 Polytherapy 22 (31)
Headache days/month 21.1 ± 0.7
Previous preventive classes failure 4.7 ± 0.3
Acute medications intake/month 25 ± 3.7
Patients with MOH 64 (91.4)
Pain intensity (NRS) 8.6 ± 0.6
MIDAS 108.1 ± 11.4
HIT-6 65.9 ± 1.2
MSQ 13.2 ± 7.5
BDI-II 17.0 ± 1.5
HDRS 14.3 ± 1.2
HARS 17.1 ± 1.7
MOS sleep scale 24.7 ± 0.7
ASC-12 6.7 ± 0.7
PCS 33.2 ± 1.3
MIG-SCOG 9.9 ± 0.6
  1. Values are mean ± standard error (SE) or number (%)
  2. ASC-12 Allodynia Symptom Checklist-12, BDI II Beck Depression Inventory II, HARS Hamilton Anxiety Rating Scale, HDRS Hamilton Depression Rating Scale, HIT-6 headache impact test-6, MIDAS migraine disability assessment scale, MIG-SCOG MIGraine attacks - Subjective COGnitive impairments scale, MOH medication overuse headache, MOS Medical Outcomes Study, MSQ migraine-specific quality-of-life questionnaire, NRS numerical rating scale, PCS Pain Catastrophizing Scale
\